Table 1.

 Relationship between immunoreactivity of ERRb, ERRg, and clinicopathological findings in PCa (n = 107)

Clinical findings		ERRβ immunoreactive score†			ERRγ immunoreactive score†
		Low (n = 71)	High (n = 36)	P‐values	Low (n = 47)	High (n = 60)	P‐values
Serum PSA (ng/mL)		14.7 ± 13.9	19.7 ± 26.2	0.2	13.0 ± 13.7	18.9 ± 21.9	0.11
Gleason score	≤7	42	22	0.99	27	37	0.68
	≥8	29	14		20	23
Pathological T stage	≤3a	48	24	0.89	27	45	0.08
	≥3b	23	12		20	15
Pathological N stage	0	61	32	0.99	39	54	0.44
	1	10	4		8	6

†ERRb and ERRg immunoreactive scores of 0–4 and 5–8 were defined as low and high immunoreactivity, respectively. ERR, estrogen‐related receptor; PCa, prostate cancer; PSA, prostate‐specific antigen.